A New Hematocrit Measurement Method Using a Chemiluminescence Biosensor and Its Application in a Chemiluminescence Immunoassay Platform for Myocardial Markers Detection with Whole Blood Samples
Open Access
- 21 December 2022
- journal article
- research article
- Published by MDPI AG in Biosensors
- Vol. 13 (1) , 3
Abstract
The accuracy and precision of analyte concentrations measured in whole blood by chemiluminescence immunoassay (CLIA) have been significantly affected by erythrocytes, which leads to poor application of whole blood CLIA in clinical practice. In this work, a chemiluminescence biosensing optical platform for blood hematocrit (HCT) analysis using MAGICL 6000 (Getein Biotechnology, Nanjing, China) was designed, implemented, and fully characterized. The developed method was successfully applied to determine various HCT levels of human blood from 0% to 65%, with a correlation coefficient of 0.9885 compared with the conventional method (Sysmex XE 5000, Kobe, Japan). A mathematical model was developed to quantitatively evaluate the impact of HCT on the results of two sample types (whole blood vs. plasma). Combining the established HCT method and mathematical model with CLIA on MAGICL 6000, the precision was significantly improved by almost 20%. Comparison studies using whole blood samples and corresponding plasma samples showed that the square of the correlation coefficients of troponin I (cTnI), myoglobin (MYO), creatine kinase MB (CK-MB), and N-terminal pro-hormone brain natriuretic peptide (NT-proBNP) were increased to 0.9992, 0.9997, 0.9996, and 0.9994, respectively, showing a great potential for clinical application.Keywords
Funding Information
- Jiangsu Provincial Special Program of Medical Science (BE2019749, 62071119, BA2020016, SKLOD2022OF05)
- National Natural Science Foundation of China (BE2019749, 62071119, BA2020016, SKLOD2022OF05)
- Jiangsu Provincial Key Research and Development Program (BE2019749, 62071119, BA2020016, SKLOD2022OF05)
- Open Funding of State Key Laboratory of Oral Diseases (BE2019749, 62071119, BA2020016, SKLOD2022OF05)
This publication has 54 references indexed in Scilit:
- Evaluation of analytical performance of the Pathfast® cardiac troponin IClinical Chemistry and Laboratory Medicine (CCLM), 2009
- Hematocrit Influences Immunoassay Performance for the Measurement of Tacrolimus in Whole BloodTherapeutic Drug Monitoring, 2005
- Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methodsClinical Biochemistry, 2005
- N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failureHeart, 2003
- Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk populationEuropean Heart Journal, 1999
- Editorials How to use natriuretic peptide levels for diagnosis and prognosisEuropean Heart Journal, 1999
- Immunoreactive amino‐terminal pro‐brain natriuretic peptide (NT‐PROBNP): a new marker of cardiac impairmentClinical Endocrinology, 1997
- Recommendations for reference method for haemoglobinometry in human blood (ICSH standard 1995) and specifications for international haemiglobinocyanide standard (4th edition).Journal of Clinical Pathology, 1996
- The reaction of hemin with H2O2European Journal of Biochemistry, 1989
- The reaction of ferriprotoporphyrin with hydrogen peroxide in alkaline solutionsArchives of Biochemistry and Biophysics, 1960